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Abstract 
Objectives: To compare the effect of systemic adjunctive use of azithromycin with 
amoxicillin/metronidazole to scaling and root planing (SRP) in a clinical study.  
Materials and Methods: Data from 60 individuals with chronic periodontitis were 
evaluated after full-mouth SRP. Antibiotics were given from the first day of SRP, in 
the test group (n=29) azithromycin for three days, in the control group (n=31) 
amoxicillin/metronidazole for seven days. Probing depth (PD), attachment level (AL) 
and bleeding on probing (BOP) were recorded at baseline and after 3 and 12 
months. Gingival crevicular fluid was analyzed for MMP-8 and IL-1beta levels. 
Subgingival plaque was taken for assessment of the major bacteria associated with 
periodontitis.  
Results: In both groups, PD, AL and BOP were significantly reduced (p<0.001).  
A few significant differences between the groups were found; AL and BOP were 
significantly better in the test than in the control group at the end of the study 
(p=0.020 and 0.009). Periodontopathogens were reduced most in the test group.  
Conclusions: A noninferiority of the treatment with azithromycin in comparison with 
amoxicillin / metronidazole can be stated. The administration of azithromycin could 
be an alternative to the use of amoxicillin/metronidazole adjunctive to SRP in patients 
with moderate or severe chronic periodontitis, however a randomized placebo 
controlled multicenter study is needed.  
Clinical Relevance: Application of azithromycin as a single antibiotic for three days 
might be considered as an additional adjunctive antibiotic to SRP in selected 
patients.    
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Scaling and root planing (SRP) is an effective causative method for infection control 
in the treatment of periodontal disease [1]. Subgingival mechanical debridement 
results in a mean attachment gain of 2.16 mm in pockets with an initial depth ≥ 7 mm 
[2]. Different systemic and local antimicrobial adjuncts have been shown to improve 
the outcome of SRP [3-5]. Metronidazole in combination with SRP is more effective 
than SRP alone in terms of probing depth reduction and clinical attachment level gain 
[6]. Amoxicillin/metronidazole is an effective adjunct to SRP of chronic periodontitis 
and an often studied treatment procedure [3]. The clinical and microbiological results 
of SRP are better with the combination of amoxicillin /metronidazole also in type 2 
diabetes patients than without adjunctive antibiotics [7]. At the moment the use of 
amoxicillin/metronidazole is largely debated considering multiple aspects of the 
advantages and disadvantages of antibiotics in general and in periodontology [8].   
More and more studies evaluated azithromycin as an adjunctive antibiotic in 
periodontal treatment. Azithromycin is effective against Gram-negative aerobic and 
anaerobic bacteria, is slowly released to the tissue and has a long half-life in 
periodontal tissues [9]. It is a macrolide which inhibits bacterial protein synthesis, 
quorum sensing, reduces biofilm formation and modulates the host response [10]. 
Azithromycin suppresses in vitro the formation and activity of osteoclasts [11] and it 
diminishes the production of inflammatory mediators in gingival fibroblasts stimulated 
by Porphyromonas gingivalis LPS [12].  
By using a daily single dose of 500 mg for three days higher reduction of probing 
depth and more attachment level gain than by SRP with placebo have been reported 
[13-15]. However there are also studies that did not reveal any additional effect of 
azithromycin regarding the outcome of SRP [16-19]. Long lasting beneficial effects of 
repeated adjunctive azithromycin on gingival inflammation, BOP and tooth mobility 
were observed up to 192 weeks in an observational clinical study [20].  
To our best knowledge up to now no study has compared the adjunctive effect of 
azithromycin to that of amoxicillin and metronidazole in conjunction with nonsurgical 
periodontal therapy. Therefore the aim of the present study was to evaluate in a 
prospective randomized clinical trial over 12 months the two antibiotic regimens by 
analyzing clinical, biochemical and microbiological data. The hypothesis to test of this 
study was that there is inferiority of adjunctive treatment with azithromycin in relation 
to the treatment with amoxicillin/metronidazole regarding changes of the clinical 
parameters PD, AL and BOP.  
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Material and Methods 
 
Patients 
Following approval of the study by the Ethics Commission (#240-2011) of the 
University of Leipzig Medical Faculty, 96 randomly selected patients were screened 
and asked to participate in the study. Sixty-two volunteers (29 female and 33 male) 
gave written and informed consent to their participation in the randomised clinical 
study in a private dental practice (A.B.). In obtaining the informed consents and in 
conducting the study, the principles outlined in the Declaration of Helsinki, as revised 
in 2000, were followed. Only individuals with moderate or severe chronic periodontitis 
[21] were included in the study. In addition two other inclusion criteria were at least 5 
sites with probing depths (PD) ≥ 5 mm and a minimum of 14 teeth. The interproximal 
plaque index (API, [22]) was required to be ≤ 35% after two initial prophylaxis and 
instruction sessions. Results of the API ≤ 35% reflect a sufficient hygiene to start with 
periodontal therapy [22]. Individuals were excluded if they had taken antibiotics in the 
three months prior to the study or if they had received periodontal treatment during 
the previous year. Pregnancy, nursing, smoking, chronic diseases such as diabetes 
mellitus or rheumatoid arthritis and allergy to ingredients in the drug were also criteria 
for exclusion.  
All treatment was performed by the same dentist (A.B.). To avoid bias, another 
investigator blinded to the treatment (A.F.) collected plaque, GCF and assessed the 
clinical data. A computer-generated randomization table was used to recruit and 
blindly randomize 62 participants either to the control (n=31) or experimental group 
(n=31) with a 1:1 allocation ratio. Allocation concealment was obtained using a 
sealed opaque envelope containing the treatment (number of allocation table) to the 
specific subject. The sealed envelope containing treatment assignment was opened 
immediately after SRP. All measurements were carried out by a single masked 
examiner (A.F.). For intra-examiner calibration the repeated repeated measurements 
of the PD of one quadrant in 10 patients were used for reliability testing resulting in κ 
of 0.91. He did not perform the SRP and was unaware of the treatment assignment. 
Documentation was performed by an assistant. 
The clinical variables PD, attachment level (AL) and bleeding on probing (BOP) of all 
teeth were determined in a six-point measurement per tooth (mesiobuccal, buccal, 
distobuccal, mesiooral, oral and distooral) with a manual periodontal probe (PCP-
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UNC 15, Hu-Friedy Manufacturing Co., Chicago, IL, USA) at three appointments: 
before SRP (baseline, t1), after three (t3) and 12 months (t4). At the same time, 
samples of the subgingival biofilm and gingival crevicular fluid (GCF) were taken from 
the deepest site per quadrant. To analyze a short-time effect on host response, GCF 
was sampled in addition 14 days after SRP (t2). 
For sampling GCF, sterile paper strips (Periopaper; Oraflow Inc., Smithtown, New 
York, USA) were placed at the entrance of the periodontal pocket for 30 s. This 
intracrevicular superficial method [23] ensures that the subgingival biofilm in the 
pocket is not destroyed. Following this, endodontic paper points (ISO 60, Roeko 
GmbH, Langenau, Germany) were inserted into the pocket until resistance was felt 
and were left in place for 30 s. The strips were pooled and placed into a tube 
containing proteinase inhibitors (Sigma-Aldrich, St. Louis, MO, USA). All samples 
were stored at -20°C immediately after collection and transferred to the laboratory 
within one month where the plaque samples were again stored at -20°C, and the 
GCF samples at -80°C until analysis.  
 
Therapy and follow-up treatment  
Under local anaesthesia with articaine hydrochloride/epinephrine hydrochloride 
(Ultracain D-S, Sanofi-Aventis, Frankfurt/Main, Germany), the participants received 
full-mouth SRP in two sessions carried out during two consecutive days using 
hand and ultrasonic instruments. All of the patients used a chlorhexidine digluconate 
mouthrinse (Chlorhexamed forte 0.2%, GlaxoSmithKline Healthcare, Bühl, Germany) 
for one minute twice daily during the first seven days after SRP. Careful normal oral 
hygiene with toothbrush and interdental brushes was performed. 
Antibiotics were given from the first day of SRP. The patients of the test group (n=31) 
received 500 mg/d azithromycin (Azithromycin 500 mg, Hexal AG, Holzkirchen, 
Germany) for three days. 
Amoxicillin (3x500 mg/d, Amoxihexal 500 mg, Hexal AG, Holzkirchen, Germany) and 
metronidazole (3x400 mg/d, Metronidazol 400 mg, Hexal AG, Holzkirchen, Germany) 
were administered to the patients of the control group for 7 days. No blinding of the 
packing and pharmaceutical form has been performed, the drugs were provided by a 
public pharmacy. During the following three or seven days a dental assistant of the 
private practice reminded the patient to take the next or remaining doses. After intake 
of the tablets, patients were asked to return the tablet packagings to the dental 
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practice.  
Every three months careful supportive periodontal therapy was performed by an 
experienced clinician (A.B.). During the appointment of supportive periodontal care 
remotivation and reinstruction have been performed. The patients were controlled for 
exact drug use. The participants were asked to address the private practice in case 
of adverse events due to the antibiotic therapy. 
 
Biochemical and microbiological analysis 
Before analyzing, GCF samples were eluted at 4°C overnight into 750 µl phosphate-
buffered saline containing proteinase inhibitors. From the eluates, the levels of 
interleukin (IL)-1β and matrixmetalloprotease (MMP)-8 were determined by using 
commercially available enzyme-linked immunosorbent assay (ELISA) kits (R&D 
Systems Europe Ltd., Abingdon, UK) according to the manufacturer’s instructions. 
The detection levels of the kits were 2 pg/site for IL-1β and 100 pg/site for MMP-8.   
Microbiological analysis was made as described recently [24]. In short, DNA was 
extracted by using the Chelex method [25]. Following, the microIDent®plus11 test 
(Hain Lifescience, Nehren, Germany) was used according to the manufacturer’s 
description. The test is able to identify 11 periodontopathogenic bacterial species 
after two PCR runs and a subsequent reverse hybridization. Intensity of staining of 
the strips was used for semi-quantification. Two qualified investigators determined 
independently the score (0 – no band (negative), 1 – weak band (low load), 2 – clear 
band (moderate load), 3 – strong band (high load), 4 – very strong band (very high 
load)). Both the reference bands and the hybridization controls were used for 
adjustment. The qualitative results were used for an additional analysis: the positive 
results were counted for the major periodontopathogens (Aggregatibacter 
actinomycetemcomitans, P. gingivalis, Tannerella forsythia and Treponema 
denticola) and for all analysed bacterial species (in addition Parvimonas micra, 
Fusobacterium nucleatum / necrophorum, Campylobacter rectus, Eubacterium 
nodatum, Eikenella corrodens, Capnocytophaga sp.). 
 
Data analysis 
The null hypothesis of our study was that there are statistically significant differences 
in the clinical parameters PD, AL and BOP between the test and control groups with 
inferiority of the test group. Change of probing depth (PD) at the 12-months 
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appointment was set as the primary outcome and used to determine sample size. A 
mean difference of 1 mm in observed PD with a standard deviation of 1 mm between 
two groups or two examination dates would require ≥ 16 patients per group in order 
to detect a significant difference (p ≤ 0.05) with a test power of 80% (GraphPad 
StatMate v.2.0 for Mac, GraphPad Software, San Diego, CA, U.S.A.). Secondary 
outcome variables were changes of PD after three months, in the number of sites 
with PD ≥ 5 mm, occurrence of BOP, mean AL, levels of MMP-8 and IL-1β as well as 
the counts of selected pathogenic bacteria associated with periodontitis after three 
and 12 months.  
Statistical analysis of the clinical and laboratory data was performed using the 
software SPSS® Statistics 21.0 (IBM Corporation, New York, NY, USA). Unit of 
analysis in all statistical tests was the individual. For both intra- and inter-group 
comparisons, non-parametric tests (Wilcoxon test for paired samples and Mann 
Whitney U –test, respectively) were used. A level of α ≤ 0.05 was considered as 
being significant.  
 
Results 
The study was performed in 2012 and 2013. Fig. 1 presents the study flow adapted 
to Moher et al. [26]. The demographic data of these 60 patients are summarized in 
Table 1.  
No severe adverse effects of the different antibiotics were observed during the study. 
No significant differences were seen at API. Changes of the clinical data during the 
study are presented in Table 2. BOP was not significantly different between the 
groups after three months, but after 12 months lower in the test group than in the 
controls (p = 0.009). The changes of BOP were significantly higher in the test group 
during the whole study period (p < 0.001). AL was significantly better in the test 
group at the end of the study (p = 0.020). The mean change of PD after 12 months 
as well as the change of AL during the first three months and during the whole study 
period were significantly higher in the test group than in the controls (p = 0.001, p = 
0.001, p = 0.021). There were significantly fewer sites with AL ≥ 5 mm after three and 
12 months in the test group in comparison with the control group (p = 0.019, p = 
0.037). 
The levels of MMP-8 and IL-1β are given in Table 3. No significant differences 
occurred at MMP-8.  
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The analysis of sums of positive results for analyzed bacteria revealed no significant 
difference between the test and control groups at baseline. After three and 12 
months lower numbers of positive results were detected in the test group than in the 
control group (Table 4).. There were also no significant differences between test and 
control groups at the semi-quantitative analysis of 11 tested bacterial species at 
baseline. Of the major periodontopathogens lower counts of T. denticola, P. 
intermedia, were detected in the test group than in the control group (p = 0.031, 
0.016) after three months. After 12 months still the counts of T. denticola were 
significantly lower in the test group (p = 0.002)(Fig. 2).  
 
Discussion 
This study analyzed the effects of two different regimes of adjunctive administration 
of systemic antibiotics during SRP in cases with moderate to severe chronic 
periodontitis on clinical, biochemical and microbiological results. To our best 
knowledge and literature search such a study approach has not been published until 
now. The test hypothesis can be rejected, inferiority of adjunctive antibiotic treatment 
with azithromycin was not observed. The change of mean PD after 12 months was 
set as the primary outcome. The difference between the groups was only 0.32 mm in 
median (significance in favor of azithromycin). From the clinical point of view PD, AL 
and BOP were improved in both groups at every follow-up appointment underlining 
the efficacy of both treatments. Favorable 12-months results for adjunctive 
azithromycin in comparison to SRP only were reported for the treatment of 
aggressive periodontitis, here the difference of mean PD difference was about 1 mm 
[14]. Comparing different adjunctive treatment regimens in chronic periodontitis 
azithromycin was as effective as metronidazole in reducing mean PD [27] or did not 
show significant differences to exclusive SRP only after one year [17].    
The advantage of the use of azithromycin is the short course of administration of the 
antibiotic which may contribute to the patients´compliance. We did not see any side 
effect and no patient stopped the intake of either azithromycin or the combination of 
amoxicillin and metronidazole.    
A systematic review calculated a mean reduction of 1.41 mm for PD and of 0.94 mm 
for AL after SRP with adjunctive amoxicillin/metronidazole [4]. In comparison to these 
results our study revealed 1.3 mm improvement of PD and 1.1 mm attachment gain 
for the control group with adjunctive amoxicillin/metronidazole. These results are 
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reasonable for SRP in a private dental practice. Most studies on SRP with and 
without adjunctive antibiotics have been conducted at universities. The conditions 
there may differ to a certain extent from those in private dental practices.  Further 
attachment loss is reduced when patients are treated at universities conditions and 
when regular supportive periodontal care is provided [28]. During the supportive 
periodontal therapy a better stability of attachment level was found by specialist care 
as compared to general practice [29]. In our study the treatment was performed by a 
dentist with special interest in periodontology in a general dental practice. It should 
be taken into account that this is the normal clinical situation for the most patients. In 
general, the analyzed bacteria were more reduced after adjunctive azithromycin than 
after the combined administration of amoxicillin and metronidazole. After three and 
12 months T. denticola was found to be significant lower in the subgingival biofilm in 
the test group. This finding is important because T. denticola is strongly related to 
further periodontal breakdown in periodontitis and to the recurrence of the disease 
[30]. T. denticola lives in metabolic symbioses with P. gingivalis [31] and is difficult to 
suppress by combined mechanical and antibiotic therapy [32]. Azithromycin activity is 
not limited on killing bacteria, it decreases also the bacterial virulence. In 
subinhibitory concentrations it inhibits the fimbrial production of P. gingivalis [33], 
reduces biofilm formation and decreases the counts of P. gingivalis within the biofilm 
[34]. Azithromycin is of interest for the treatment of Pseudomonas aeruginosa 
infections. Although not acting growth inhibitory it suppresses the expression of 
virulence factors, biofilm formation and quorum sensing [35].      
On the other hand, azithromycin interferes with immune cells. In our study the levels 
of the inflammatory markers MMP-8 and IL-1β were determined immediately 14 days 
up to one year after starting the intake of the antibiotics. IL-1β belonging to the 
interleukin-1 cytokines is induced by proinflammatory agents such as 
lipopolysaccharide, TNF and IL-1β itself; it accounts for neutrophil infiltration and 
tissue turnover via inducing matrix metalloproteinases (MMPs) [36]. MMPs as a 
family of enzymes which degrade extracellular matrix and basement membrane 
components are mostly produced in a latent form; activation most involves tissue, 
plasma and bacterial proteinases together with oxidative stress [37]; MMP-8 
(neutrophil collagenase) targets native collagen [38].    
The only striking result was seen after 14 days in the test group, here the levels of IL-
1β decreased significantly (p=0.030) and those of MMP-8 by trend (p = 0.061) 
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suggesting an influence of azithromycin on host cells. In vitro, the uptake of 
azithromycin by monocytic cells leads to an enhanced release of inflammatory 
mediators (e.g. IL-1β) and reduced killing which are reversed after 24 hours [39]. The 
mRNA expression and following the protein levels of IL-10 are increased dose-
dependently by azithromycin in activated monocytes [40]. In healthy volunteers it was 
shown, that IL-8 and IL-1β levels increased up to 24 hours after intake of 
azithromycin and returned to baseline after 28 days [41]. Azithromycin reduces the 
amount of gingival crevicular fluid as well as several cytokines (IL-1β, IL-8, TNF-α) in 
the gingival crevicular fluid [42]. Our results are comparable to those of another study 
in chronic periodontitis patients, where MMP-8 levels decreased immediately 14 days 
after treatment, while no difference to baseline was found 3 months later [17].  
Our study has limitations. No negative control, an SRP without adjunctive antibiotic 
treatment, was included into the study. Although the examiner was not aware of the 
treatment groups, the drugs were not blinded to the clinician and no placebo was 
used. Inclusion criteria were at least 5 sites with PD ≥ 5 mm. However it should be 
mentioned that the majority of the sites with ≥ 5 mm had a PD of 5 mm. This might 
influence the favorable results regarding azithromycin. The results of this one-center 
study need to be confirmed in a randomized placebo-controlled multicenter trial. 
Although comparing here two groups with adjunctive antibiotics, the use should be 
limited to selected cases. An absolute precondition is a well performed mechanical 
plaque control since it is well known that antibiotics are less active within biofilms [43, 
44]. Irrespective of this a global problem is the development of resistance which is 
clearly associated with the consumption of antibiotics [45].  
Within in the limits of the present study it can be summarized that azithromycin might 
be an alternative when an adjunctive antibiotic treatment of moderate to severe 
chronic periodontitis during SRP is needed.  
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Figures 
 
Assessed for eligibility (n=96)
Lost to follow-up (n=0)
Excluded  (n=34)
•  Not meeting inclusion criteria (n=30)
•  Refused to participate (n=4)
Allocated to intervention        
(test group: n=31) 
Received SRP+ azithromycin 
(n=31)
Allocated to intervention 
(control group: n=31)
Received SRP + 
amoxicillin+metronidazole (n=31)
Allocation
3 month
Follow up
12 month
Follow up
Analysis
Randomized (n=62)
Lost to follow-up (n=2)
• patient moved to other city (n=1)
• patient had to intake antibiotics 
for other reason (n=1)
Lost to follow-up (n=0)
Analyzed (n=29)
• Excluded from analysis (n=0)
Lost to follow-up (n=0)
Analyzed (n=31)
• Excluded from analysis (n=0)
Fig. 1. Flowchart (adapted to Moher et al. [26]) of the study analysing the effect of 
azithromycin in comparison to amoxicillin/metronidazole as an adjunct after scaling 
and root planing 
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¶¶ ¶ ¶ ¶
** ** **
(a)
(b)
baseline 3 months 12 months
baseline 3 months 12 months
 
 
 Fig. 2. Semiquantitative loads of periodontopathogenic bacteria (A. 
actinomycetemcomitans, P. gingivalis, T. forsythia, T. denticola, P. intermedia, F. 
nucleatum/necrophorum, C. rectus, E. corrodens, P. micra, E. nodatum, 
Capnocytophaga sp. at baseline as well as three and 12 months after SRP with 
adjunctive azithromycin (test) and amoxicillin/ metronidazole ( control)  
¶p<0.05, ¶¶p<0.01 significant inter-group difference, *p<0.05, **p<0.01 significant 
difference to baseline 
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Table 1. Demographic data in the test (azithromycin) and control 
(amoxicillin/metronidazole) groups at baseline 
 
 
Variable Test group       
(n=29) 
Control group 
(n=31) 
 
Age (years; mean±SD) 54.66 ± 8.89  53.48 ± 8.07  
Range (years) 31 – 68  32 - 64  
Male (n) 13 18  
Female (n) 16 13  
    
SD – standard deviation; n – number 
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Table 2 Clinical variables (median, 5 and 95 percentile) at baseline, after three and 12 months incl. differences (diff.) and statistical 
analysis in the test (azithromycin) and control (amoxicillin/metronidazole) groups 
Ntest group=29 
Ncontrol group= 31 
Baseline  3 months  12 months  Difference 3 months - 
baseline 
Difference 12 months 
- baseline 
      
BOP (%) 
   Test group 
   Control group 
 
45.0 (24.0, 63.5) 
37.0 (30.6, 65.0) 
 
15.0 (11.0, 25.0)*** 
15.0 (10.2, 21.0)*** 
 
13.0 (10.0, 19.0)***,¶¶ 
15.0 (10.6, 21.2)*** 
 
29.0 (8.5, 49.0) 
23.0 (14.2, 48.0) 
 
30.0 (10.5, 50.5)¶ 
22.0 (16.0, 44.8) 
GI (%) 
   Test group 
   Control group 
 
44.0 (26.5, 65.0) 
41.0 (33.8, 64.4) 
 
21.0 (18.0, 25.5)*** 
23.0 (17.6, 27.8)*** 
 
20.0 (16.0, 22.5)*** 
20.0 (16.6, 25.2)*** 
 
24.0 (5.0, 45.0) 
18.0 (10.0, 43.8) 
 
26.0 (6.0, 44.5) 
21.0 (13.8, 42.2) 
Median PD (mm) 
   Test group 
   Control group 
 
4.07 (3.72, 4.40) 
4.05 (3.43, 4.69) 
 
2.88 (2.43, 3.32)*** 
2.90 (2.57, 3.45)*** 
 
2.70 (2.24, 3.24)*** 
2.75 (2.39, 3.33)*** 
 
1.20 (0.85, 1.58) 
1.13 (0.82, 1.39) 
 
1.50 (1.08, 2.67)¶¶ 
1.28 (0.91, 1.62) 
Median AL (mm) 
   Test group 
   Control group 
 
4.34 (3.86, 5.56) 
4.33 (3.82, 6.41) 
 
3.20 (2.71, 4.31)***,¶ 
3.41 (2.98, 5.28)*** 
 
3.04 (2.55, 4.31)***,¶ 
3.30 (2.78, 5.04)*** 
 
1.11 (0.72, 1.49)¶¶ 
0.89 (0.62, 1.28) 
 
1.18 (0.87, 1.68)¶ 
1.05 (0.72, 2.33) 
Sites PD ≥5 mm (n)       
   Test group 
   Control group 
 
19.0 (5.0, 51.0) 
21.0 (5.2, 76.8) 
 
0 (0, 16.0)*** 
0 (0, 13.2)*** 
 
0 (0, 15.5)*** 
0 (0, 9.6)*** 
 
18.0 (3.5, 45.0) 
21.0 (3.2, 63.6) 
 
18.0 (3.5, 45.5) 
21.0 (3.2, 67.8) 
Median PD in sites PD ≥5 
mm at baseline (mm)  
   Test group 
   Control group 
 
 
5.14 (5.00, 5.97) 
5.21 (5.00, 6.23) 
 
 
3.56 (3.02, 4.48)*** 
3.67 (3.34, 4.46)*** 
 
 
3.50 (2.75, 4.48)*** 
3.44 (3.05, 4.35)*** 
 
 
1.62 (1.12, 2.08) 
1.51 (1.08, 2.30) 
 
 
1.81 (1.31, 2.71) 
1.76 (1.19, 2.56) 
Sites AL ≥5 mm (n)   
  Test group 
   Control group 
 
45.0 (16.5, 108.5) 
50.0 (21.4, 149.0) 
 
6.0 (0, 57.0)***,¶ 
9.0 (3.0, 106.0)*** 
 
6.0 (0, 55.5)***,¶ 
9.0 (2.0, 97.6)*** 
 
33.0 (16.5, 63.0) 
29.0 (17.8, 64.2) 
 
34.0 (16.5, 64.5) 
34.0 (17.8, 76.2) 
Median AL in sites AL ≥5 mm 
at baseline (mm) 
   Test group 
   Control group 
 
 
5.29 (4.63, 6.21)¶ 
5.48 (5.07, 6.68) 
 
 
3.90 (3.36, 5.05)***,¶¶ 
4.21 (3.74, 5.53) 
 
 
3.78 (3.24, 4.95)***,¶ 
4.02 (3.46, 5.52)*** 
 
 
1.34 (0.92, 1.71)¶¶ 
1.15 0.76, 1.56) 
 
 
1.45 (0.98, 1.89) 
1.36 (0.74, 2.86) 
Wilcoxon’ signed rank test for paired samples: *p<0.05, **p<0.01, ***p<0.001, each compared with baseline 
Mann Whitney test between the groups: ¶p<0.05, ¶¶<0.01, ¶¶¶<0.001 
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n –number; BOP – bleeding on probing; GI – gingival index; PD – probing depth; AL – attachment level  
 
 
 
 
 
Table 3 Biomarkers (median, 5 and 95 percentile) in the test (azithromycin) and control (amoxicillin/metronidazole) groups at baseline, 
after 14 days as well as three and 12 months   
Ntest group=29 
Ncontrol group= 31 
Baseline  14 d  3 months  12 months 
     
MMP-8 (ng/site) 
   Test group 
   Control group 
 
12.33 (2.41, 38.93) 
10.40 (1.41, 33.85) 
 
9.35 (0.97, 22.65) 
7.45 (3.43, 31.83) 
 
11.72 (2.22, 31.82) 
11.85 (2.52, 33.72) 
 
6.97 (0.52, 32.40) 
8.46 (3.30, 25.39) 
IL-1β (pg/site) 
   Test group 
   Control group 
 
31.70 (3.06, 287.86) 
23.67 (4.65, 152.25) 
 
17.18 (2.18, 155.07)* 
23.23 (1.69, 568.60) 
 
48.48 (2.50, 279.80) 
33.62 (2.63, 257.46) 
 
18.52 (1.62, 496.36) 
31.04 (2.51, 248.95) 
Wilcoxon’ signed rank test for paired samples:  
*p<0.05 compared with baseline  
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Table 4  Numbers (% per group) of the positive results of major periodontopathogenic bacteria (Aggregatibacter 
actinomycetemcomitans, Porphyromonas gingivalis, Tannerella forsythia, Treponema denticola) and of the 11 analyzed species (in 
addition Prevotella intermedia, Parvimonas micra, Fusobacterium nucleatum / necrophorum, Campylobacter rectus, Eubacterium 
nodatum, Eikenella corrodens, Capnocytophaga sp. in the test (azithromycin) and control (amoxicillin/metronidazole) groups at 
baseline as well as three and 12 months after SRP with adjunctive azithromycin (test) and with amoxicillin/ metronidazole (control) incl. 
statistics (p values) 
 Baseline 3 months 12 months All time-points 
(p) 
 3 months – 
baseline (p) 
12 months – 
baseline (p) 
Major periodontopathogens 
Test group (n=29) 
No detection 
1 species 
2 species 
3 species 
4 species   
 
Control group (n=31) 
 
 
4 (13.8) 
5 (17.2) 
6 (20.7) 
13 (44.8) 
1 (3.4) 
 
 
9 (31.0) 
7 (24.1) 
6 (20.7) 
7 (24.1) 
0 
 
 
9 (31.0) 
7 (24.1) 
8 (27.6) 
4 (13.8) 
1 (3.4) 
 
 
 
 
 
0.028 
 
 
 
 
 
 
 
 
 
0.044 
 
 
 
 
 
 
 
 
 
0.039 
 
 
 
 
 
 
 
No detection 
1 species 
2 species 
3 species 
4 species 
Test vs. control (p)    
1 (3.2) 
7 (22.6) 
5 (16.1) 
18 (58.1) 
0 
0.470 
5 (16.1) 
2 (6.5) 
10 (32.3) 
13 (41.9) 
1 (3.2) 
0.023 
6 (19.4) 
4 (12.9) 
8 (25.8) 
11 (35.5) 
2 (6.5) 
0.047 
0.412 0.528 0.220 
       
Analyzed 11  periodontopathogens 
Test group (n=29) 
No detection 
1-2 species 
3-4 species 
5-6 species 
≥7 species    
 
Control group (n=31) 
 
 
0 
2 (6.9) 
7 (24.1) 
11 (37.9) 
9 (31.0) 
 
 
2 (6.9) 
4 (13.8) 
10 (34.5) 
10 (34.5) 
3 (10.3) 
 
 
1 (3.4) 
4 (13.8) 
12 (41.4) 
8 (27.6) 
4 (13.8) 
 
 
0.015 
 
 
 
 
 
 
 
 
0.016 
 
 
 
 
 
 
 
0.047 
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No detection 
1-2 species 
3-4 species 
5-6 species 
≥7 species    
Test vs. control (p)    
0 
1 (3.2) 
8 (25.8) 
8 (25.8) 
14 (45.2) 
0.520 
1 (3.2)1 
1 (3.2) 
9 (29.0) 
9 (29.0) 
11 (35.5) 
0.024 
0 
2 (6.5) 
8 (25.8) 
10 (32.3) 
11 (35.5) 
0.039 
0.364 0.183 0.229 
 
 
